Prothena Corporation plc (PRTA)
PRTA Stock Price Chart
Explore Prothena Corporation plc interactive price chart. Choose custom timeframes to analyze PRTA price movements and trends.
PRTA Company Profile
Discover essential business fundamentals and corporate details for Prothena Corporation plc (PRTA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Dec 2012
Employees
67.00
Website
https://www.prothena.comCEO
Gene G. Kinney
Description
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
PRTA Financial Timeline
Browse a chronological timeline of Prothena Corporation plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is -$0.39, while revenue estimate is $425.83k.
Earnings released on 7 May 2026
EPS came in at $0.60 surpassing the estimated -$0.31 by +293.55%, while revenue for the quarter reached $51.08m , beating expectations by +6.22k%.
Earnings released on 19 Feb 2026
EPS came in at -$0.44 surpassing the estimated -$0.45 by +2.22%, while revenue for the quarter reached $21.00k , missing expectations by -98.43%.
Earnings released on 6 Nov 2025
EPS came in at -$0.67 falling short of the estimated -$0.60 by -11.67%, while revenue for the quarter reached $2.42m , beating expectations by +262.25%.
Earnings released on 4 Aug 2025
EPS came in at -$1.86 falling short of the estimated -$1.11 by -67.57%, while revenue for the quarter reached $4.42m , missing expectations by -33.42%.
Earnings released on 8 May 2025
EPS came in at -$1.12 falling short of the estimated -$0.92 by -21.74%, while revenue for the quarter reached $2.83m , missing expectations by -81.56%.
Earnings released on 20 Feb 2025
EPS came in at -$1.08 falling short of the estimated -$1.02 by -5.88%, while revenue for the quarter reached $2.12m , missing expectations by -71.82%.
Earnings released on 12 Nov 2024
EPS came in at -$1.10 surpassing the estimated -$1.18 by +6.78%, while revenue for the quarter reached $970.00k , missing expectations by -21.14%.
Earnings released on 8 Aug 2024
EPS came in at $1.22 surpassing the estimated -$1.05 by +216.19%, while revenue for the quarter reached $132.01m , beating expectations by +1.13k%.
Earnings released on 8 May 2024
EPS came in at -$1.34 falling short of the estimated -$1.21 by -10.74%, while revenue for the quarter reached $50.00k , missing expectations by -97.28%.
Earnings released on 15 Feb 2024
EPS came in at -$1.26 falling short of the estimated -$1.23 by -2.44%, while revenue for the quarter reached $316.00k , missing expectations by -85.30%.
Earnings released on 2 Nov 2023
EPS came in at $0.38 surpassing the estimated -$0.32 by +218.75%, while revenue for the quarter reached $84.87m , beating expectations by +103.56%.
Earnings released on 3 Aug 2023
EPS came in at -$1.03 falling short of the estimated -$0.92 by -11.96%, while revenue for the quarter reached $4.02m , missing expectations by -11.08%.
Earnings released on 4 May 2023
EPS came in at -$0.89 falling short of the estimated -$0.83 by -7.23%, while revenue for the quarter reached $2.17m , missing expectations by -52.01%.
Earnings released on 23 Feb 2023
EPS came in at $0.12 surpassing the estimated -$0.47 by +125.53%, while revenue for the quarter reached $49.92m , beating expectations by +577.38%.
Earnings released on 3 Nov 2022
EPS came in at -$0.97 falling short of the estimated -$0.31 by -212.90%, while revenue for the quarter reached $1.52m , missing expectations by -93.98%.
Earnings released on 8 Aug 2022
EPS came in at -$0.88 falling short of the estimated -$0.51 by -72.55%, while revenue for the quarter reached $1.31m , missing expectations by -92.36%.
Earnings released on 5 May 2022
EPS came in at -$0.78 surpassing the estimated -$0.85 by +8.24%, while revenue for the quarter reached $1.15m , missing expectations by -85.74%.
Earnings released on 17 Feb 2022
EPS came in at -$0.71 surpassing the estimated -$0.74 by +4.05%, while revenue for the quarter reached $1.17m , missing expectations by -83.53%.
Earnings released on 4 Nov 2021
EPS came in at $2.13 falling short of the estimated $2.28 by -6.58%, while revenue for the quarter reached $139.17m , missing expectations by -0.63%.
Earnings released on 5 Aug 2021
EPS came in at $0.58 falling short of the estimated $1.00 by -42.00%, while revenue for the quarter reached $60.07m , missing expectations by -14.43%.
PRTA Stock Performance
Access detailed PRTA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
